Health Economic Assessment of Optimal Biological Treatment for Moderate-to-Severe Psoriasis

ConclusionsThis research suggests that the optimal first-line treatment in the UK is adalimumab biosimilar. The optimal second-line and third-line treatments depend on the magnitude of confidential discounts applied to the biologic treatments.
Source: Clinical Drug Investigation - Category: Drugs & Pharmacology Source Type: research